Behavioral, Virologic, and Immunologic Factors Associated With Acquisition and Severity of Primary Epstein-Barr Virus Infection in University Students
Background. University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity. Methods. EBV antibody-negative freshmen participated in monthly surveil...
Saved in:
Published in | The Journal of infectious diseases Vol. 207; no. 1; pp. 80 - 88 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Oxford University Press
01.01.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background. University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity. Methods. EBV antibody-negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay. Results. Of 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing (< .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8⁺ T-cells but not in numbers of CD4⁺ T-cells during acute infection. Severity of illness correlated positively with both blood EBV load (P = .015) and CD8⁺ lymphocytosis (P = .0003). Conclusions. Kissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8⁺ lymphocytosis correlated with disease severity. |
---|---|
AbstractList | Background.
University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein–Barr virus (EBV) infection and the virologic and immune correlates of disease severity.
Methods.
EBV antibody–negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay.
Results.
Of 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing (
P
< .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8
+
T-cells but not in numbers of CD4
+
T-cells during acute infection. Severity of illness correlated positively with both blood EBV load (
P
= .015) and CD8
+
lymphocytosis (
P
= .0003).
Conclusions.
Kissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8
+
lymphocytosis correlated with disease severity. Background. University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity. Methods. EBV antibody-negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay. Results. Of 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing (< .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8⁺ T-cells but not in numbers of CD4⁺ T-cells during acute infection. Severity of illness correlated positively with both blood EBV load (P = .015) and CD8⁺ lymphocytosis (P = .0003). Conclusions. Kissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8⁺ lymphocytosis correlated with disease severity. University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity.BACKGROUNDUniversity students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity.EBV antibody-negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay.METHODSEBV antibody-negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay.Of 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing (P < .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8(+) T-cells but not in numbers of CD4(+) T-cells during acute infection. Severity of illness correlated positively with both blood EBV load (P = .015) and CD8(+) lymphocytosis (P = .0003).RESULTSOf 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing (P < .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8(+) T-cells but not in numbers of CD4(+) T-cells during acute infection. Severity of illness correlated positively with both blood EBV load (P = .015) and CD8(+) lymphocytosis (P = .0003).Kissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8(+) lymphocytosis correlated with disease severity.CONCLUSIONSKissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8(+) lymphocytosis correlated with disease severity. University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity. EBV antibody-negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay. Of 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing (P < .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8(+) T-cells but not in numbers of CD4(+) T-cells during acute infection. Severity of illness correlated positively with both blood EBV load (P = .015) and CD8(+) lymphocytosis (P = .0003). Kissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8(+) lymphocytosis correlated with disease severity. Background. University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity. Methods. EBV antibody-negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay. Results. Of 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing (P < .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8 super(+) T-cells but not in numbers of CD4 super(+) T-cells during acute infection. Severity of illness correlated positively with both blood EBV load (P = .015) and CD8 super(+) lymphocytosis (P = .0003). Conclusions. Kissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8 super(+) lymphocytosis correlated with disease severity. |
Author | Mullan, Beth D. Thomas, William Balfour, Henry H. Hogquist, Kristin A. Ed, Julie A. Knight, Jennifer A. Vezina, Heather E. Schmeling, David O. Odumade, Oludare A. |
AuthorAffiliation | 4 Division of Biostatistics, School of Public Health , University of Minnesota Medical School , Minneapolis 1 Department of Laboratory Medicine and Pathology 3 Department of Experimental and Clinical Pharmacology 2 Department of Pediatrics |
AuthorAffiliation_xml | – name: 2 Department of Pediatrics – name: 4 Division of Biostatistics, School of Public Health , University of Minnesota Medical School , Minneapolis – name: 1 Department of Laboratory Medicine and Pathology – name: 3 Department of Experimental and Clinical Pharmacology |
Author_xml | – sequence: 1 givenname: Henry H. surname: Balfour fullname: Balfour, Henry H. – sequence: 2 givenname: Oludare A. surname: Odumade fullname: Odumade, Oludare A. – sequence: 3 givenname: David O. surname: Schmeling fullname: Schmeling, David O. – sequence: 4 givenname: Beth D. surname: Mullan fullname: Mullan, Beth D. – sequence: 5 givenname: Julie A. surname: Ed fullname: Ed, Julie A. – sequence: 6 givenname: Jennifer A. surname: Knight fullname: Knight, Jennifer A. – sequence: 7 givenname: Heather E. surname: Vezina fullname: Vezina, Heather E. – sequence: 8 givenname: William surname: Thomas fullname: Thomas, William – sequence: 9 givenname: Kristin A. surname: Hogquist fullname: Hogquist, Kristin A. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27110422$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23100562$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkktr3DAUhUVJaSZpl122aFPoIm70sCV7U5iEJB0ItJCmXRpZljJ38EgTSR7IH-nvjR1Ppw8oXQmk79x7ru45QgfOO4PQa0o-UFLxU3C2hXi6gihy8QzNaMFlJgTlB2hGCGMZLavqEB3FuCKE5FzIF-iQcUpIIdgM_TgzS7UFH1R3gr9B8J2_A32ClWvxYr3u3XSBL5VOPkQ8j9FrUMm0-DukJZ7r-x4iJPDuSXNjtiZAesDe4i8B1io84ItNTAZcdqZCGHv0ES-cNfpJBA7fOhhEcVTdpL41LsWX6LlVXTSvducxur28-Hr-Kbv-fLU4n19nOpcsZbZgSjBaClLmBa9IXuaEyqJsLLes0Yo0zDAliS0JbRtCc1lSXbW8og2XrRX8GH2c6m76Zm1aPfQefqLeTM5rr6D-88XBsr7z25oXjMtKDgXe7woEf9-bmOo1RG26Tjnj-1hTkTPBCiGK_6NMciZZWVYD-vZ3W3s_P_c2AO92gIpadTYopyH-4iSlJGcjl02cDj7GYOweoaQe81NP-amn_Aw8_4vXkNS4qGF66P6pejOpVnEIyb5FTiUTVFT8EZ1V2CE |
CODEN | JIDIAQ |
CitedBy_id | crossref_primary_10_3390_vaccines9111290 crossref_primary_10_1111_bjh_14339 crossref_primary_10_1111_apt_14933 crossref_primary_10_1016_j_smim_2022_101652 crossref_primary_10_1080_07448481_2020_1726927 crossref_primary_10_1038_s41598_020_70129_4 crossref_primary_10_1093_cid_ciy464 crossref_primary_10_1016_j_celrep_2013_11_041 crossref_primary_10_1136_bcr_2022_250081 crossref_primary_10_1007_s40588_019_00120_9 crossref_primary_10_1016_j_vaccine_2016_04_012 crossref_primary_10_1128_JVI_00382_17 crossref_primary_10_3390_v14122709 crossref_primary_10_3390_ijerph18084080 crossref_primary_10_7759_cureus_29784 crossref_primary_10_1016_j_vaccine_2015_10_024 crossref_primary_10_1016_j_cell_2022_08_026 crossref_primary_10_1371_journal_ppat_1005549 crossref_primary_10_3390_cells11172757 crossref_primary_10_3389_fonc_2020_01723 crossref_primary_10_46310_tjim_1303184 crossref_primary_10_22625_2072_6732_2020_12_4_93_100 crossref_primary_10_1093_cid_ciu206 crossref_primary_10_1099_jmm_0_000616 crossref_primary_10_1128_JVI_01466_17 crossref_primary_10_26565_2313_6693_2021_43_08 crossref_primary_10_1080_15321819_2019_1705483 crossref_primary_10_1002_14651858_CD011487_pub2 crossref_primary_10_1093_cid_ciu204 crossref_primary_10_1093_infdis_jiv340 crossref_primary_10_3389_fimmu_2021_640918 crossref_primary_10_3389_fimmu_2020_581419 crossref_primary_10_1016_j_jemermed_2018_01_031 crossref_primary_10_3389_fimmu_2016_00323 crossref_primary_10_1371_journal_ppat_1008477 crossref_primary_10_1128_CVI_00674_15 crossref_primary_10_1016_j_jpag_2020_06_018 crossref_primary_10_1182_blood_2014_01_553024 crossref_primary_10_1093_protein_gzab034 crossref_primary_10_1016_j_trre_2016_12_001 crossref_primary_10_3923_biotech_2022_110_119 crossref_primary_10_1016_j_jiph_2015_06_011 crossref_primary_10_1055_a_1822_4067 crossref_primary_10_1007_s12250_018_0028_z crossref_primary_10_1016_j_coviro_2016_08_010 crossref_primary_10_1038_cti_2016_48 crossref_primary_10_1002_eji_202048655 crossref_primary_10_3390_pathogens11070809 crossref_primary_10_1016_j_coviro_2015_08_002 crossref_primary_10_3390_microorganisms9112191 crossref_primary_10_1016_j_msard_2021_103288 crossref_primary_10_1016_j_vaccine_2012_09_041 crossref_primary_10_3390_vaccines9060655 crossref_primary_10_33667_2078_5631_2019_3_32_407__24_28 crossref_primary_10_1128_JVI_01932_15 crossref_primary_10_1186_s13052_023_01498_5 crossref_primary_10_1093_cid_ciu342 crossref_primary_10_7189_jogh_10_010404 crossref_primary_10_1093_ije_dyu118 crossref_primary_10_1099_vir_0_066712_0 crossref_primary_10_4236_aim_2020_103005 crossref_primary_10_1093_infdis_jiv114 crossref_primary_10_1007_s12098_020_03319_7 crossref_primary_10_1016_j_bmhimx_2015_12_001 crossref_primary_10_1093_infdis_jis647 crossref_primary_10_7180_kmj_2018_33_3_347 crossref_primary_10_1016_j_coviro_2015_08_014 crossref_primary_10_1111_ane_12294 crossref_primary_10_1016_j_exer_2021_108483 crossref_primary_10_1099_jgv_0_000332 crossref_primary_10_15789_2220_7619_MCO_1481 crossref_primary_10_3389_fimmu_2019_00146 crossref_primary_10_1111_jicd_12278 crossref_primary_10_1371_journal_pone_0212027 crossref_primary_10_3343_alm_2018_38_5_458 crossref_primary_10_1038_s41598_017_18195_z crossref_primary_10_1038_s41598_020_76344_3 crossref_primary_10_4049_jimmunol_1401811 crossref_primary_10_3390_v8040105 crossref_primary_10_1038_cti_2016_28 crossref_primary_10_31586_Microbiology_0403_02 crossref_primary_10_1371_journal_ppat_1011970 crossref_primary_10_1186_s12876_019_1021_1 crossref_primary_10_1080_1744666X_2021_1847642 crossref_primary_10_1016_S2444_3409_16_30017_6 crossref_primary_10_1016_j_imbio_2020_151907 crossref_primary_10_1038_nature17655 crossref_primary_10_1016_j_jviromet_2017_02_016 crossref_primary_10_1016_j_amsu_2018_10_010 crossref_primary_10_1016_j_cpha_2016_12_010 crossref_primary_10_1016_j_diagmicrobio_2020_115295 crossref_primary_10_1016_j_jcv_2022_105267 crossref_primary_10_1016_j_cmi_2015_07_015 crossref_primary_10_1084_jem_20161846 crossref_primary_10_1111_apa_14728 crossref_primary_10_1038_s41467_019_11878_3 crossref_primary_10_1093_infdis_jit096 crossref_primary_10_1016_j_crad_2020_05_011 crossref_primary_10_11603_1681_2727_2019_3_10633 crossref_primary_10_1172_jci_insight_85687 crossref_primary_10_1111_prd_12273 crossref_primary_10_1016_j_meegid_2023_105443 crossref_primary_10_1186_s12887_022_03770_9 crossref_primary_10_3389_fonc_2018_00211 crossref_primary_10_3390_v16030463 crossref_primary_10_1177_1352458513505693 crossref_primary_10_12688_f1000research_11197_1 crossref_primary_10_3390_v8020051 crossref_primary_10_1371_journal_ppat_1005286 crossref_primary_10_3389_fimmu_2017_00197 crossref_primary_10_29413_ABS_2021_6_4_15 crossref_primary_10_1016_j_vetmic_2015_06_002 crossref_primary_10_1371_journal_ppat_1004746 crossref_primary_10_1309_LM9OWRF64OGQODEA crossref_primary_10_1371_journal_pone_0311130 crossref_primary_10_3389_fimmu_2023_1271236 crossref_primary_10_1016_S2352_4642_21_00198_X crossref_primary_10_1093_femsre_fuy044 crossref_primary_10_1136_jnnp_2020_322941 crossref_primary_10_4049_jimmunol_1303211 crossref_primary_10_17116_otorino20218604179 crossref_primary_10_1371_journal_ppat_1010738 crossref_primary_10_1111_nyas_12937 crossref_primary_10_1016_j_epsc_2020_101680 crossref_primary_10_1189_jlb_0313173 crossref_primary_10_1098_rstb_2018_0296 crossref_primary_10_1016_j_jneuroim_2024_578343 crossref_primary_10_1371_journal_pone_0175574 crossref_primary_10_1093_jpids_piu076 crossref_primary_10_1038_s41390_019_0591_5 crossref_primary_10_1371_journal_pone_0085422 crossref_primary_10_1016_j_med_2018_04_020 crossref_primary_10_3389_fonc_2019_00104 crossref_primary_10_1002_iid3_666 crossref_primary_10_1186_1471_2334_14_417 crossref_primary_10_1007_s40472_016_0102_0 crossref_primary_10_1128_mBio_01841_17 crossref_primary_10_4049_jimmunol_1301046 crossref_primary_10_1371_journal_pone_0115836 crossref_primary_10_1016_j_it_2014_01_003 crossref_primary_10_1111_petr_14471 crossref_primary_10_1016_j_diagmicrobio_2014_03_022 crossref_primary_10_1186_s12985_015_0441_y crossref_primary_10_1146_annurev_immunol_032414_112326 crossref_primary_10_1097_TP_0000000000003130 crossref_primary_10_1186_s13052_023_01457_0 crossref_primary_10_3390_vaccines10091399 crossref_primary_10_1111_pin_13469 crossref_primary_10_1249_JSR_0000000000000887 crossref_primary_10_1371_journal_pntd_0005815 crossref_primary_10_1128_JVI_01293_15 crossref_primary_10_3389_fimmu_2021_757302 crossref_primary_10_1097_01_NPR_0000469261_28614_88 crossref_primary_10_1111_ijd_14887 crossref_primary_10_1080_14760584_2017_1293529 crossref_primary_10_1097_TP_0000000000001767 crossref_primary_10_1017_S0950268819000335 crossref_primary_10_3390_microorganisms7120686 crossref_primary_10_1038_cti_2014_27 crossref_primary_10_1212_NXI_0000000000200332 crossref_primary_10_1093_infdis_jit321 crossref_primary_10_1111_tid_13010 crossref_primary_10_1016_j_coviro_2014_02_005 crossref_primary_10_1111_ijcp_14690 crossref_primary_10_3389_fimmu_2016_00607 crossref_primary_10_1371_journal_pone_0226436 crossref_primary_10_1016_j_jpeds_2021_07_009 crossref_primary_10_1038_s41582_023_00775_5 crossref_primary_10_1007_s00415_017_8656_z crossref_primary_10_1360_SSV_2024_0187 crossref_primary_10_1360_SSV_2024_0186 crossref_primary_10_2217_bmm_2020_0456 crossref_primary_10_3389_fimmu_2022_1028972 crossref_primary_10_29254_2077_4214_2021_3_161_220_224 crossref_primary_10_3390_v16010124 crossref_primary_10_1002_cti2_1451 crossref_primary_10_1182_blood_2013_11_538686 crossref_primary_10_3390_cancers15061914 crossref_primary_10_1016_j_jcv_2014_05_019 crossref_primary_10_1371_journal_ppat_1010137 crossref_primary_10_1371_journal_pone_0135512 crossref_primary_10_1186_s12985_017_0859_5 crossref_primary_10_1016_j_msard_2022_103678 crossref_primary_10_1016_j_semnephrol_2016_05_013 crossref_primary_10_1097_INF_0000000000002484 crossref_primary_10_1111_bjh_19255 crossref_primary_10_29254_2077_4214_2021_4_162_159_164 crossref_primary_10_1371_journal_pone_0261665 crossref_primary_10_3389_fimmu_2021_677027 crossref_primary_10_1007_s00431_021_04345_z crossref_primary_10_1128_JVI_02885_13 crossref_primary_10_3389_fmicb_2017_02666 crossref_primary_10_1172_JCI86923 crossref_primary_10_1016_j_cyto_2020_155395 crossref_primary_10_3389_fimmu_2019_02193 crossref_primary_10_1186_s12967_015_0415_2 crossref_primary_10_3389_fimmu_2020_00267 crossref_primary_10_3389_fepid_2025_1518559 crossref_primary_10_1007_s13665_020_00245_z crossref_primary_10_1080_14760584_2019_1605906 crossref_primary_10_37436_2308_5274_2020_3_15 crossref_primary_10_1016_j_jcv_2018_03_001 crossref_primary_10_1371_journal_pone_0078474 crossref_primary_10_1097_TP_0000000000000354 crossref_primary_10_26565_2617_409X_2021_8_06 crossref_primary_10_1007_s10875_020_00790_x crossref_primary_10_1038_s41598_023_31858_4 crossref_primary_10_1371_journal_pone_0081881 crossref_primary_10_1038_cti_2015_1 crossref_primary_10_3389_fimmu_2024_1466339 crossref_primary_10_3389_fcimb_2021_605258 crossref_primary_10_7759_cureus_60329 crossref_primary_10_1016_j_biomaterials_2020_120158 crossref_primary_10_4049_jimmunol_1401513 crossref_primary_10_4103_IJO_IJO_1213_23 crossref_primary_10_1007_s40588_023_00203_8 crossref_primary_10_3390_vaccines7040217 |
Cites_doi | 10.1017/CBO9780511545313.054 10.1371/journal.ppat.1001051 10.1111/j.1365-2141.2005.05452.x 10.1016/j.immuni.2008.02.020 10.1016/S0140-6736(64)91524-7 10.1073/pnas.59.1.94 10.1128/CMR.00044-10 10.1084/jem.187.9.1395 10.1111/1523-1747.ep12499958 10.1111/j.0105-2896.2010.00897.x 10.1093/bioinformatics/btm044 10.1086/523815 10.1086/505400 10.1089/088922201750251981 10.1086/491740 10.1016/S0140-6736(86)90531-3 10.1084/jem.20112401 10.1146/annurev.immunol.25.022106.141553 10.1371/journal.ppat.1000496 10.4049/jimmunol.173.4.2410 10.1182/blood.V98.13.3739 10.1002/ijc.2910340506 |
ContentType | Journal Article |
Copyright | Copyright © 2013 Oxford University Press on behalf of the Infectious Diseases Society of America 2014 INIST-CNRS The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: . 2012 |
Copyright_xml | – notice: Copyright © 2013 Oxford University Press on behalf of the Infectious Diseases Society of America – notice: 2014 INIST-CNRS – notice: The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: . 2012 |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 7T5 7U9 H94 5PM |
DOI | 10.1093/infdis/jis646 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts |
DatabaseTitleList | MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1537-6613 |
EndPage | 88 |
ExternalDocumentID | PMC3523797 23100562 27110422 10_1093_infdis_jis646 41726169 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | Minnesota |
GeographicLocations_xml | – name: Minnesota |
GrantInformation_xml | – fundername: NIAID NIH HHS grantid: P01AI35296 – fundername: NIAID NIH HHS grantid: P01 AI035296 – fundername: NIAID NIH HHS grantid: F31 AI084524 – fundername: NIAID NIH HHS grantid: F31AI084524 – fundername: NCI NIH HHS grantid: T32 CA009138 |
GroupedDBID | --- -DZ -~X ..I .2P .I3 .XZ .ZR 08P 0R~ 123 1KJ 1TH 29K 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 70D 85S AABZA AACGO AACZT AAHBH AAHTB AAJKP AAJQQ AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWTL ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPEJ ABPLY ABPPZ ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ABZBJ ACGFO ACGFS ACGOD ACHIC ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFZL AFIYH AFOFC AFXAL AFYAG AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQVQM ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BR6 BTRTY BVRKM C45 CDBKE CS3 CZ4 D-I DAKXR DCCCD DIK DILTD DU5 D~K EBS ECGQY EE~ EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IH2 IOX IPSME J21 JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B LSO LU7 MHKGH MJL ML0 N9A NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TR2 W2D W8F WH7 X7H YAYTL YKOAZ YXANX ~91 AAYXX CITATION .55 .GJ 3O- 41~ AAFWJ AAPGJ AAWDT ABDPE ABSMQ ACFRR ACPQN ACVCV ACZBC ADMTO AEKPW AFFNX AFFQV AFHKK AFQQW AFSHK AGKRT AGMDO AHGBF AI. AJDVS APJGH AQDSO AQKUS AVNTJ BZKNY EIHJH HQ3 HTVGU IQODW J5H MBLQV MVM N4W NEJ OBFPC O~Y P0- TMA VH1 X7M Y6R ZE2 ZGI ZXP CGR CUY CVF ECM EIF NPM 7X8 7T5 7U9 H94 5PM |
ID | FETCH-LOGICAL-c472t-f52a62186084539048401758bf3f2bca0b2e2a70f801db014781c9d391b37df63 |
ISSN | 0022-1899 1537-6613 |
IngestDate | Thu Aug 21 13:55:36 EDT 2025 Thu Jul 10 23:24:41 EDT 2025 Fri Jul 11 00:35:03 EDT 2025 Mon Jul 21 06:03:03 EDT 2025 Mon Jul 21 09:13:29 EDT 2025 Tue Jul 01 02:51:50 EDT 2025 Thu Apr 24 22:55:43 EDT 2025 Sun Aug 24 12:10:32 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Gammaherpesvirinae Virus Infection Primary infection Herpesviridae Epstein Barr virus Student |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c472t-f52a62186084539048401758bf3f2bca0b2e2a70f801db014781c9d391b37df63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Presented in part: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, 18 September 2011. Abstract V494. |
OpenAccessLink | https://academic.oup.com/jid/article-pdf/207/1/80/16866890/jis646.pdf |
PMID | 23100562 |
PQID | 1273272889 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3523797 proquest_miscellaneous_1642625665 proquest_miscellaneous_1273272889 pubmed_primary_23100562 pascalfrancis_primary_27110422 crossref_primary_10_1093_infdis_jis646 crossref_citationtrail_10_1093_infdis_jis646 jstor_primary_41726169 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2013-01-01 |
PublicationDateYYYYMMDD | 2013-01-01 |
PublicationDate_xml | – month: 01 year: 2013 text: 2013-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Oxford |
PublicationPlace_xml | – name: Oxford – name: United States |
PublicationTitle | The Journal of infectious diseases |
PublicationTitleAlternate | J Infect Dis |
PublicationYear | 2013 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Crawford ( key 20170511122816_JIS646C18) 2006; 43 Miller ( key 20170511122816_JIS646C11) 2008; 28 Williams ( key 20170511122816_JIS646C21) 2005; 129 Melbye ( key 20170511122816_JIS646C5) 1984; 34 Hislop ( key 20170511122816_JIS646C15) 2007; 25 Hjalgrim ( key 20170511122816_JIS646C6) 2007 Castiglione ( key 20170511122816_JIS646C23) 2007; 23 Naher ( key 20170511122816_JIS646C19) 1992; 98 Callan ( key 20170511122816_JIS646C14) 1998; 187 Silins ( key 20170511122816_JIS646C7) 2001; 98 Hadinoto ( key 20170511122816_JIS646C24) 2009; 5 Henle ( key 20170511122816_JIS646C2) 1968; 59 Balfour ( key 20170511122816_JIS646C8) 2005; 192 Sandalova ( key 20170511122816_JIS646C13) 2010; 6 Odumade ( key 20170511122816_JIS646C17) 2011; 24 de-The ( key 20170511122816_JIS646C3) 1975; 11 Doisne ( key 20170511122816_JIS646C12) 2004; 173 Welsh ( key 20170511122816_JIS646C22) 2010; 235 Balfour ( key 20170511122816_JIS646C9) 2007; 196 Epstein ( key 20170511122816_JIS646C1) 1964; 1 Sixbey ( key 20170511122816_JIS646C20) 1986; 2 Riddell ( key 20170511122816_JIS646C16) 2001; 17 Henle ( key 20170511122816_JIS646C4) 1967; 27 Odumade ( key 20170511122816_JIS646C10) 2012; 209 15813855 - Br J Haematol. 2005 Apr;129(2):266-74 22393125 - J Exp Med. 2012 Mar 12;209(3):471-8 14107961 - Lancet. 1964 Mar 28;1(7335):702-3 11739180 - Blood. 2001 Dec 15;98(13):3739-44 18468462 - Immunity. 2008 May;28(5):710-22 4295480 - Cancer Res. 1967 Dec;27(12):2442-6 1314867 - J Invest Dermatol. 1992 May;98(5):791-3 16804839 - Clin Infect Dis. 2006 Aug 1;43(3):276-82 23100564 - J Infect Dis. 2013 Jan 1;207(1):6-8 5242134 - Proc Natl Acad Sci U S A. 1968 Jan;59(1):94-101 J Infect Dis. 2013 Jun 15;207(12):1940 18190249 - J Infect Dis. 2007 Dec 15;196(12):1724-6 20808900 - PLoS Pathog. 2010;6(8):e1001051 20536568 - Immunol Rev. 2010 May;235(1):244-66 16206064 - J Infect Dis. 2005 Nov 1;192(9):1505-12 9565632 - J Exp Med. 1998 May 4;187(9):1395-402 2877273 - Lancet. 1986 Nov 15;2(8516):1122-4 21233512 - Clin Microbiol Rev. 2011 Jan;24(1):193-209 17341499 - Bioinformatics. 2007 Jun 1;23(11):1371-7 191375 - IARC Sci Publ. 1975;(11 Pt 2):3-16 6094363 - Int J Cancer. 1984 Nov 15;34(5):619-23 11429120 - AIDS Res Hum Retroviruses. 2001 Jun 10;17(9):789-97 15294954 - J Immunol. 2004 Aug 15;173(4):2410-8 17378764 - Annu Rev Immunol. 2007;25:587-617 19578433 - PLoS Pathog. 2009 Jul;5(7):e1000496 |
References_xml | – start-page: 929 volume-title: Human herpesviruses: biology, therapy, and immunoprophylaxis year: 2007 ident: key 20170511122816_JIS646C6 article-title: The epidemiology of EBV and its association with malignant disease doi: 10.1017/CBO9780511545313.054 – volume: 6 start-page: e1001051 year: 2010 ident: key 20170511122816_JIS646C13 article-title: Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1001051 – volume: 129 start-page: 266 year: 2005 ident: key 20170511122816_JIS646C21 article-title: The immune response to primary EBV infection: a role for natural killer cells publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2005.05452.x – volume: 28 start-page: 710 year: 2008 ident: key 20170511122816_JIS646C11 article-title: Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines publication-title: Immunity doi: 10.1016/j.immuni.2008.02.020 – volume: 1 start-page: 702 year: 1964 ident: key 20170511122816_JIS646C1 article-title: Virus particles in cultured lymphoblasts from Burkitt's lymphoma publication-title: Lancet doi: 10.1016/S0140-6736(64)91524-7 – volume: 59 start-page: 94 year: 1968 ident: key 20170511122816_JIS646C2 article-title: Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.59.1.94 – volume: 24 start-page: 193 year: 2011 ident: key 20170511122816_JIS646C17 article-title: Progress and problems in understanding and managing primary Epstein-Barr virus infections publication-title: Clin Microbiol Rev doi: 10.1128/CMR.00044-10 – volume: 187 start-page: 1395 year: 1998 ident: key 20170511122816_JIS646C14 article-title: Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo publication-title: J Exp Med doi: 10.1084/jem.187.9.1395 – volume: 98 start-page: 791 year: 1992 ident: key 20170511122816_JIS646C19 article-title: Subclinical Epstein-Barr virus infection of both the male and female genital tract–indication for sexual transmission publication-title: J Invest.Dermatol doi: 10.1111/1523-1747.ep12499958 – volume: 235 start-page: 244 year: 2010 ident: key 20170511122816_JIS646C22 article-title: Heterologous immunity between viruses publication-title: Immunol Rev doi: 10.1111/j.0105-2896.2010.00897.x – volume: 23 start-page: 1371 year: 2007 ident: key 20170511122816_JIS646C23 article-title: Simulating Epstein-Barr virus infection with C-ImmSim publication-title: Bioinformatics doi: 10.1093/bioinformatics/btm044 – volume: 196 start-page: 1724 year: 2007 ident: key 20170511122816_JIS646C9 article-title: Epstein-Barr virus vaccine for the prevention of infectious mononucleosis—and what else? publication-title: J Infect Dis doi: 10.1086/523815 – volume: 27 start-page: 2442 year: 1967 ident: key 20170511122816_JIS646C4 article-title: Immunofluorescence, interference, and complement fixation technics in the detection of the herpes-type virus in Burkitt tumor cell lines publication-title: Cancer Res – volume: 43 start-page: 276 year: 2006 ident: key 20170511122816_JIS646C18 article-title: A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis publication-title: Clin Infect Dis doi: 10.1086/505400 – volume: 17 start-page: 789 year: 2001 ident: key 20170511122816_JIS646C16 article-title: A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease publication-title: AIDS Res Hum Retroviruses doi: 10.1089/088922201750251981 – volume: 192 start-page: 1505 year: 2005 ident: key 20170511122816_JIS646C8 article-title: A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis publication-title: J Infect Dis doi: 10.1086/491740 – volume: 2 start-page: 1122 year: 1986 ident: key 20170511122816_JIS646C20 article-title: A second site for Epstein-Barr virus shedding: the uterine cervix publication-title: Lancet doi: 10.1016/S0140-6736(86)90531-3 – volume: 11 start-page: 113 year: 1975 ident: key 20170511122816_JIS646C3 article-title: Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study - a review publication-title: IARC Sci Publ – volume: 209 start-page: 471 year: 2012 ident: key 20170511122816_JIS646C10 article-title: Primary Epstein-Barr virus infection does not erode preexisting CD8 T cell memory in humans publication-title: J Exp Med doi: 10.1084/jem.20112401 – volume: 25 start-page: 587 year: 2007 ident: key 20170511122816_JIS646C15 article-title: Cellular responses to viral infection in humans: lessons from Epstein-Barr virus publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.25.022106.141553 – volume: 5 start-page: e1000496 year: 2009 ident: key 20170511122816_JIS646C24 article-title: The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1000496 – volume: 173 start-page: 2410 year: 2004 ident: key 20170511122816_JIS646C12 article-title: CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection publication-title: J Immunol doi: 10.4049/jimmunol.173.4.2410 – volume: 98 start-page: 3739 year: 2001 ident: key 20170511122816_JIS646C7 article-title: Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load publication-title: Blood doi: 10.1182/blood.V98.13.3739 – volume: 34 start-page: 619 year: 1984 ident: key 20170511122816_JIS646C5 article-title: Early primary infection and high Epstein-Barr virus antibody titers in Greenland Eskimos at high risk for nasopharyngeal carcinoma publication-title: Int J Cancer doi: 10.1002/ijc.2910340506 – reference: 9565632 - J Exp Med. 1998 May 4;187(9):1395-402 – reference: 2877273 - Lancet. 1986 Nov 15;2(8516):1122-4 – reference: 15294954 - J Immunol. 2004 Aug 15;173(4):2410-8 – reference: 6094363 - Int J Cancer. 1984 Nov 15;34(5):619-23 – reference: 11739180 - Blood. 2001 Dec 15;98(13):3739-44 – reference: 16206064 - J Infect Dis. 2005 Nov 1;192(9):1505-12 – reference: 191375 - IARC Sci Publ. 1975;(11 Pt 2):3-16 – reference: 1314867 - J Invest Dermatol. 1992 May;98(5):791-3 – reference: 16804839 - Clin Infect Dis. 2006 Aug 1;43(3):276-82 – reference: 19578433 - PLoS Pathog. 2009 Jul;5(7):e1000496 – reference: 17378764 - Annu Rev Immunol. 2007;25:587-617 – reference: 20808900 - PLoS Pathog. 2010;6(8):e1001051 – reference: 11429120 - AIDS Res Hum Retroviruses. 2001 Jun 10;17(9):789-97 – reference: 21233512 - Clin Microbiol Rev. 2011 Jan;24(1):193-209 – reference: 22393125 - J Exp Med. 2012 Mar 12;209(3):471-8 – reference: 14107961 - Lancet. 1964 Mar 28;1(7335):702-3 – reference: - J Infect Dis. 2013 Jun 15;207(12):1940 – reference: 23100564 - J Infect Dis. 2013 Jan 1;207(1):6-8 – reference: 18190249 - J Infect Dis. 2007 Dec 15;196(12):1724-6 – reference: 18468462 - Immunity. 2008 May;28(5):710-22 – reference: 17341499 - Bioinformatics. 2007 Jun 1;23(11):1371-7 – reference: 15813855 - Br J Haematol. 2005 Apr;129(2):266-74 – reference: 20536568 - Immunol Rev. 2010 May;235(1):244-66 – reference: 4295480 - Cancer Res. 1967 Dec;27(12):2442-6 – reference: 5242134 - Proc Natl Acad Sci U S A. 1968 Jan;59(1):94-101 |
SSID | ssj0004367 |
Score | 2.5225518 |
Snippet | Background. University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV)... University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and... Background. University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein–Barr virus (EBV)... |
SourceID | pubmedcentral proquest pubmed pascalfrancis crossref jstor |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 80 |
SubjectTerms | Antibodies Antibodies, Viral - blood Biological and medical sciences Blood CD8-Positive T-Lymphocytes - immunology Cytokines - blood Diseases DNA, Viral - blood Epstein Barr virus infections Epstein-Barr virus Female Fundamental and applied biological sciences. Psychology Herpesvirus 4, Human - genetics Herpesvirus 4, Human - immunology Herpesvirus 4, Human - isolation & purification Humans Incidence Infections Infectious diseases Infectious Mononucleosis - epidemiology Infectious Mononucleosis - immunology Infectious Mononucleosis - transmission Infectious Mononucleosis - virology Kaplan-Meier Estimate Killer Cells, Natural - immunology Lymphocytosis - immunology Major and Brief Reports Male Medical sciences Microbiology Minnesota - epidemiology Miscellaneous Natural killer cells Prospective Studies Risk Factors Sentinel Surveillance Severity of Illness Index Students Symptomatology T lymphocytes Universities Viral Load Viremia Virology Viruses Young Adult |
Title | Behavioral, Virologic, and Immunologic Factors Associated With Acquisition and Severity of Primary Epstein-Barr Virus Infection in University Students |
URI | https://www.jstor.org/stable/41726169 https://www.ncbi.nlm.nih.gov/pubmed/23100562 https://www.proquest.com/docview/1273272889 https://www.proquest.com/docview/1642625665 https://pubmed.ncbi.nlm.nih.gov/PMC3523797 |
Volume | 207 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwELfKEIgXBINBBkxGQrys2Ro7iZPHjbXaYFuR1oq-RUmcaEVdtrXNA3wQvgvfjnPOcVJU0OAlqlz_aXo_23f27-4IeZfAuigDKe1YURtdyR078bLUlqnMw9wDFYIpB-ezc_947H6ceJNO52eLtVQuk730-1q_kv-RKpSBXJWX7D9I1nQKBfAZ5AtPkDA87yTjQ-NjX9FVp3NcyWpG5ony_cCi3YHOq1OLA_TML-oI9iC9LafI20IWZwb_gqZpfNaRKPo3C5UT0z6M53M1SrmAZQU5XBVPskXuuMBQmYu2ztt4n-kAFdgUetG3Q81JfTzLoSJuhwWMbO6xhrK80hGCh7NSKrqagd5FenlVedUbjv7usMERwBwz0mfwtkftQw6VcMIccjROB06AuZT2snqtFjaoF7y9mDPMobuCWlyaMWFUvckHa7cPDK0FRVIFeBh8nS58d02g7vNhNBifnkaj_mR0j9xnYKGo5BlHJ58al1zuizpQvfrdOrwrDLCP3e9j5yvqEDJiFT03XsAMzTG1yjrb53cKb0snGj0hj7VQ6QEi8ynpZMUmeYDpTb9tkodnmrjxjPxooNqlBqhdCpCjLZhSDVPawJQqmNIWTKs2NUzpdU41TGkbprSCKTUwpdOCNjClNUyfk_GgP_pwbOuUIHbqCra0c4_Fvkqj1gtcj4ew_biwpXhBkvOcJWncS1jGYtHLQfGSCZj_InDSUPLQSbiQuc-3yEZxXWQvCeWuauByKUArBy03DkXGe2mgAuiJMIgt0q0lE6U6Xr5K2zKLkLfBIxRkhIK0yHtT_Qbf-08Vtyoxm1ou2BC-44cW2VmRu6nABOjoLmMWeVsDIYJNQN3sxUUG0zVywAhhggVB-Jc6vko-AdabZ5EXCJ5mBHXNB5aQRcQKrEwFFYR-9ZtielkFowcDjotQbN9h3FfkUTO3X5ON5bzM3oBKv0x2qsnzC5JzAfQ |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Behavioral%2C+Virologic%2C+and+Immunologic+Factors+Associated+With+Acquisition+and+Severity+of+Primary+Epstein-Barr+Virus+Infection+in+University+Students&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Balfour%2C+Henry+H&rft.au=Odumade%2C+Oludare+A&rft.au=Schmeling%2C+David+O&rft.au=Mullan%2C+Beth+D&rft.date=2013-01-01&rft.issn=0022-1899&rft.eissn=1537-6613&rft.volume=207&rft.issue=1&rft.spage=80&rft.epage=88&rft_id=info:doi/10.1093%2Finfdis%2Fjis646&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon |